Literature DB >> 24720596

The impact of substance P on the pathogenesis of insulin resistance leading to gestational diabetes.

Jolanta Patro-Malysza, Zaneta Kimber-Trojnar, Katarzyna Skorzynska-Dziduszko, Beata Marciniak, Dorota Darmochwal-Kolarz, Jacek Bartosiewicz, Bozena Leszczynska-Gorzelak, Jan Oleszczuk1.   

Abstract

Gestational diabetes mellitus is one of the most often medical conditions during pregnancy affecting 5-6% of all pregnancies. The etiology of gestational diabetes is not clearly understood. In obesity and diabetes mellitus type 2, abnormal insulin signaling is an important agent mediating the increase of insulin resistance. Insulin receptor substrate serine phosphorylation is a time-controlled physiological reaction in insulin signaling that has been disrupted by metabolic and inflammatory stresses to support insulin resistance. Several kinases, including inhibitor of nuclear factor ĸB kinase β (IKK β), c-Jun N-terminal kinase (JNK), mammalian target of rapamycin (mTOR), protein kinase C (PKC) and ribosomal S6 protein kinase (S6K), are activated by these stimulators of insulin resistance and phosphorylate insulin receptor substrate proteins on several serine residues in an uncontrollable method. There are an increasing number of data indicating that substance P, being one of the crucial activators of these kinases, is a potent cytokine that impairs insulin signaling. Here we discuss recent studies that expand our understanding of how substance P may contribute to the development of insulin resistance. In our opinion, there are many interesting data suggesting that substance P may be a new player in the pathogenesis of this unfavorable condition, leading not only to the development of diabetes mellitus type 2, but also gestational diabetes. Since the etiology of gestational diabetes remains unclear, there is a strong need to explore new directions, including those not directly associated with the canonical knowledge regarding this pathology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24720596     DOI: 10.2174/1389201015666140330192941

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  5 in total

1.  Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Authors:  Sergei Spitsin; Pablo Tebas; Jeffrey S Barrett; Vasiliki Pappa; Deborah Kim; Deanne Taylor; Dwight L Evans; Steven D Douglas
Journal:  JCI Insight       Date:  2017-10-05

Review 2.  Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus 2.0.

Authors:  Monika Ruszała; Aleksandra Pilszyk; Magdalena Niebrzydowska; Żaneta Kimber-Trojnar; Marcin Trojnar; Bożena Leszczyńska-Gorzelak
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

Review 3.  Effects of Probiotic Supplementation during Pregnancy on the Future Maternal Risk of Metabolic Syndrome.

Authors:  Aleksandra Obuchowska; Kamila Gorczyca; Arkadiusz Standyło; Karolina Obuchowska; Żaneta Kimber-Trojnar; Magdalena Wierzchowska-Opoka; Bożena Leszczyńska-Gorzelak
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 4.  Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus.

Authors:  Aleksandra Pilszyk; Magdalena Niebrzydowska; Zuzanna Pilszyk; Magdalena Wierzchowska-Opoka; Żaneta Kimber-Trojnar
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

5.  Predicting metabolite-disease associations based on KATZ model.

Authors:  Xiujuan Lei; Cheng Zhang
Journal:  BioData Min       Date:  2019-10-26       Impact factor: 2.522

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.